Compare Medinice SA with Similar Stocks
Dashboard
Unrated Stock - No Analysis Available
Stock DNA
Pharmaceuticals & Biotechnology
PLN 794 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.07
-7.87%
9.14
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2026)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
594.38%
0%
594.38%
6 Months
628.21%
0%
628.21%
1 Year
631.02%
0%
631.02%
2 Years
267.64%
0%
267.64%
3 Years
361.79%
0%
361.79%
4 Years
89.33%
0%
89.33%
5 Years
468.0%
0%
468.0%
Medinice SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.71%
EBIT Growth (5y)
-221.86%
EBIT to Interest (avg)
-4.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
9.43%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.65
EV to EBIT
-95.60
EV to EBITDA
-99.23
EV to Capital Employed
8.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.56%
ROE (Latest)
-7.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.40
-1.10
-118.18%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.60
-1.20
-116.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -116.67% vs 62.50% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-6.60
-4.40
-50.00%
Interest
0.00
0.10
-100.00%
Exceptional Items
-0.00
41.90
-100.00%
Consolidate Net Profit
-6.70
37.60
-117.82%
Operating Profit Margin (Excl OI)
0.00%
-24,792.60%
2,479.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -117.82% vs 837.25% in Dec 2024
About Medinice SA 
Medinice SA
Pharmaceuticals & Biotechnology
Medinice SA is a Poland-based company engaged in medical diagnostic and testing equipment business sector. The Company specializes in creating, developing and commercializing safe and minimally invasive solutions in the field of medicine, in particular cardiology and cardio surgery. Its portfolio comprises of projects, such as CathAIO, Cryoapplicator, Med-IConsole, Minimax, Pacepress and others. All of the Company's projects have a global potential. The Company cooperates with research centers in Poland and Europe. It strives to commercialize inventions brought by both co-founders of the Company and acquired projects through the sale of licenses worldwide in the production of medical devices.
Company Coordinates 
Company Details
Ul. Chmielna 132/134 , WARSZAWA None : 00-805
Registrar Details
Footer loading






